secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scienture Holdings, Inc. (SCNX)
CIK:        0001382574
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001493152-24-029787
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TRxADE HEALTH completes merger with Scienture; issues Series X preferred convertible to common
--------------------------------------------------------------------------------

- Closed merger with Scienture Inc. on July 25; Scienture holders get 291,555 common shares (19.99% of pre-deal float) and 6,826,713 Series X non-voting convertible preferred shares.
- Company to rename to Scienture Holdings, Inc. after stockholder written consent becomes effective (20 days after information statement mailed).
- Board expands to 7; Shankar Hariharan and Narasimhan Mani appointed as directors.
- CEO and CFO remain; lock-up agreements prohibit transfer of shares for 180 days post preferred stock conversion.
- Consulting agreements with Suren Ajjarapu (702,086 common shares) and Prashant Patel (614,325 common shares) effective upon termination of employment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382574/000149315224029787/0001493152-24-029787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382574/000149315224029787/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-029787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer